The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

Provided is a pharmaceutical agent for effective prophylaxis and/or treatment of a pathological condition with decreased lung compliance. The pharmaceutical agent for prophylaxis and/or treatment of a pathological condition with decreased lung compliance is characterized by having a polyamine. The polyamine includes at least one of spermine (Spm), spermidine (Spd), and putrescine (Put). The pharmaceutical agent improves lung compliance and ameliorates gas exchange dysfunction, and therefore, can ameliorate pathological conditions such as acute respiratory distress syndrome (ARDS), acute lung injury (ALI), lung diseases caused by dysfunctional endogenous pulmonary alveolar surfactant, multiple organ dysfunction syndrome (MODS), and cardiogenic pulmonary edema.

The present disclosure generally relates to improved pharmaceutical compositions useful for the treatment of diseases and disorders. More particularly, the disclosure relates to pharmaceutical compositions comprising glyceryl tribenzoate and/or glyceryl dibenzoate for the treatment of neurodegenerative disorders and peripheral diseases.

Administration via inhalation of small peptides that mimic CXCL10 (FIBROKINE™ peptides) is described. The peptides can be administered as an aerosol, such as an aerosol with a droplet size small enough to reach lung alveoli. Use of the peptides to treat fibrosis, such as lung fibrosis, is described.

Solutions comprising hypochlorous acid and methods of use are disclosed herein. The disclosed solutions are antiviral and antibacterial. The disclosed solutions may be used to treat and/or prevent a disease state or condition associated with or characterized by acute viral respiratory diseases, such as those caused by coronaviruses. The solutions may be administered by a nebulizer or a metered dose inhaler. The disclosed solutions may also be used to decontaminate surfaces. For example, the disclosed solutions may be used to decontaminate the surfaces of personal protective equipment, such as N95 face mask.

An aerosolizable formulation having one or more aerosol-forming agents; and nicotine; wherein the nicotine includes (R)-nicotine in an amount of from about 1% to about 4.5% by weight of the total nicotine.

Inhalable compositions comprising niclosamide, or a pharmaceutically acceptable salt thereof, and polyethylene glycol; aerosols of the compositions; and the pulmonary administrations for use in the treatment of viral infections, for example respiratory viral infections.

The present invention provides for a method for the treatment of a NLRP3-associated disease or condition in a subject, the method comprising the step of administering to said subject a medically active liquid in nebulized form by inhalation, wherein the medically active liquid comprises a NLRP3 inhibitor and wherein the medically active liquid is administered in nebulized form using an inhalation device.

The present application provides a method of treating a condition associated with coronavirus infection, the condition selected from acute respiratory distress, lung inflammation, systemic inflammation, or cytokine storm, the method comprising administration of furosemide or a pharmaceutically acceptable salt or hydrate thereof.

An electrically-powered inhalation device for delivery of an aerosol to the oropharynx of a user comprises respective proximal and distal portions, the proximal portion including an inlet for a liquid, the distal portion including an aerosol outlet defining a mist-exiting location and a piezo assembly including an ultrasonically vibrable mesh membrane, for producing, upon electrical activation, a mist comprising droplets of the liquid, the mesh membrane defining a mist-generating location; and an intermediate portion disposed distally from the proximal portion and proximally from the distal portion, wherein the distal portion is dimensioned to vertically span the user's oral cavity from tongue to hard-palate when the user's lips and/or teeth are transversely engaged with the intermediate portion, so as to place the mist-exiting location in fluid communication with the user's oropharynx.